Hyderabad-based startup PopVax is developing personalised mRNA Cancer Vaccine using AI, machine learning and mRNA technology. The approach aims to train the immune system to recognise cancer cells based on individual tumour genetics. Its new RNA Foundry facility could strengthen India’s biotechnology industry, although clinical trials and regulatory approval remain necessary.
Hyderabad Startup PopVax Is Building Personalised mRNA Cancer VaccineVaccines Using AI and mRNA Technology
India’s biotechnology sector is moving into a new phase. Artificial intelligence and genetic research are helping to find new ways to treat serious diseases. PopVax, a startup from Hyderabad, is working on this kind of technology. PopVax is making personalised cancer vaccines. These vaccines are made using the unique genetic features of each patient’s tumour.
Most vaccines are made to prevent infections. Personalised cancer vaccines are different. They help the immune system find and attack cancer cells that are already in the body. The special thing is that each vaccine is made using information from the patient’s own tumour. This means every person can get a vaccine made just for them.
How PopVax’s Technology Could Change Cancer Treatment
The idea behind PopVax’s approach is easy to understand. Every cancer tumour can have a different genetic profile. Even if two patients have the same type of cancer, the mutations in their tumour cells may not be the same.
This is why personalised medicine is important. It means that treatment can be made for each person, based on their own tumour.
The process starts with genetic sequencing of a patient’s tumour. Researchers look at the genetic changes and find specific targets. These targets are called neoantigens. Neoantigens can help the immune system notice and attack cancer cells.
Artificial intelligence and machine learning help study this information. They can find the best targets for making a vaccine.
Once the targets are chosen, researchers can design a vaccine using mRNA. The mRNA has instructions for the body’s cells. These instructions help the cells make special proteins or protein pieces. The immune system can learn to see these proteins. Then, it can attack cancer cells that carry them.
Lipid nanoparticles, or LNPs, are used to carry the mRNA into cells. These tiny fat-based particles protect the mRNA and help it get to the right place.
But this method is still being developed. Scientists need to prove it is safe and that it works against cancer. This proof will come from clinical trials.
Why This Development Matters for India’s Biotech Industry
PopVax is not only making a new medical product. Its project also shows a big change happening in India’s biotechnology industry.
The company has started an RNA research, development, and manufacturing center in Hyderabad. This center is called RNA Foundry and was built together with Stochastic Sciences.
This new facility will help develop and make RNA-based medicines.
Reports say PopVax plans to create over 100 personalised cancer vaccine candidates in the next 12 months. The company also says it might take only 8 to 10 weeks to make a personalised vaccine for one person.
PopVax is working on cancers that are hard to treat, like liver and pancreatic cancer.
If this technology works, it could bring new ways to treat cancer for each person. It could also make India stronger in advanced biotechnology research.
But it is important to know the difference between making a vaccine and showing that it works in real patients.
PopVax’s cancer vaccine program has not yet proven it works for people. The vaccine candidates must go through careful testing and get approval from health authorities before they can be used as treatments.
Another challenge is the cost and speed of making these vaccines. Making a separate vaccine for each patient needs special tests, advanced production, and strict quality control.
So, making these vaccines affordable and possible to produce in large numbers will be very important for their future.
The Bigger Picture
The development of personalised cancer vaccines shows that healthcare is moving towards treatments made for each person’s unique genes.
For India, this is more than just cancer research. It also means new chances in AI-based drug development, RNA medicine making, and advanced medical studies.
PopVax’s work is still at an early stage. It is too soon to call it a major breakthrough in cancer treatment. But the company’s progress is important. It shows that Indian startups are working hard to create new medical technology, instead of only relying on solutions from other countries
